Cargando…
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
The COVID-19 pandemic remains uncontrolled despite the rapid rollout of safe and effective SARS-CoV-2 vaccines, underscoring the need to develop highly effective antivirals. In the setting of waning immunity from infection and vaccination, breakthrough infections are becoming increasingly common and...
Autores principales: | Schäfer, Alexandra, Martinez, David R., Won, John J., Moreira, Fernando R., Brown, Ariane J., Gully, Kendra L., Kalla, Rao, Chun, Kwon, Du Pont, Venice, Babusis, Darius, Tang, Jennifer, Murakami, Eisuke, Subramanian, Raju, Barrett, Kimberly T, Bleier, Blake J., Bannister, Roy, Feng, Joy Y., Bilello, John P., Cihlar, Tomas, Mackman, Richard L., Montgomery, Stephanie A., Baric, Ralph S., Sheahan, Timothy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452096/ https://www.ncbi.nlm.nih.gov/pubmed/34545367 http://dx.doi.org/10.1101/2021.09.13.460111 |
Ejemplares similares
-
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
por: Schäfer, Alexandra, et al.
Publicado: (2022) -
Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential
por: Martinez, David R., et al.
Publicado: (2023) -
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
por: Cox, Robert M., et al.
Publicado: (2021) -
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2
por: Feng, Joy Y., et al.
Publicado: (2022) -
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
por: Pruijssers, Andrea J., et al.
Publicado: (2020)